Colistin is a last-resort antibiotic for treating infections due to multidrug-resistant enterobacterial isolates. The emergence of chromosomal mutations in genes involved in the modification of lipopolysaccharide, e.g. in pmrAB, is responsible for colistin resistance [1, 2] . However, the major source of concern is related to the recent discovery of plasmid-mediated colistin resistance genes (mcr-1 to -3) owing to the risk of spread of colistin resistance [2, 3] . In Escherichia coli, chromosomally encoded PmrAB mutations and plasmid-mediated colistin resistance are responsible for low levels of colistin resistance [colistin minimum inhibitory concentrations
The objective of this study was to determine the level of colistin resistance resulting from the combination of chromosomal mutations and plasmid-mediated mcr-1 gene in E. coli.
Four E. coli isolates were used in this study, with isolates FRO and MAL being recovered from human urine samples and isolate 41331 from an animal sample. The colistin-susceptible E. coli reference strain K12 was used for mating-out assays. MICs of colistin were determined by broth microdilution method (BMD) as recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (http://www.eucast.org). Briefly, BMD manual panels were prepared extemporaneously in non-treated 96-well polystyrene microplates (Sarstedt, Nümbrecht, Germany). Dilutions of colistin sulfate (Sigma-Aldrich, St Louis, MO) ranging from 0.12-128 mg/L were made in cation-adjusted MuellerHinton broth. The results were interpreted based on EUCAST recommendations, with susceptibility and resistance breakpoints being at ≤2 mg/L and >2 mg/L, respectively.
Isolate FRO showed decreased susceptibility to colistin, with an MIC of 2 mg/L, and sequencing of the pmrAB genes identified an amino acid substitution (L110*) in the PmrB protein known to be responsible for an increased colistin MIC [4] . Isolate MAL showed low-level colistin resistance (MIC = 8 mg/L) and sequencing identified an amino acid substitution (T114P) in the HAMP domain of the PmrB protein ( Table 1) . Neither of the isolates presented mutations in phoP, phoQ or mgrB genes.
Plasmid p41331 recovered from E. coli isolate 41331 (colistin MIC = 8 mg/L) carried both the mcr-1 gene and the bla CTX-M-1 gene encoding resistance to ticarcillin and broad-spectrum cephalosporins.
To determine the level of colistin resistance resulting from acquisition of the plasmid-mediated mcr-1 gene in E. coli isolates MAL and FRO, plasmid p41331 was first transferred into E. coli K12 by mating-out assay and was then transferred into the colistinresistant E. coli FRO and MAL isolates, respectively. To avoid selection with colistin that could be responsible for acquisition of additional mutations, the E. coli transconjugants carrying plasmid p41331 were selected using Luria-Bertani agar plates supplemented with ticarcillin (100 mg/L). Presence of the mcr-1 gene in transconjugants was confirmed by PCR using specific primers as described previously [6] .
Determination of the MICs of the transconjugants revealed that the E. coli K12 transconjugant (p41331-K12) presented a low level of resistance (MIC = 4 mg/L), whereas E. coli FRO and MAL transconjugants (harbouring plasmid p41331 in addition to mutations in PmrB) exhibited higher MICs (8 mg/L and 32 mg/L, respectively) ( Table 1) . Acquisition of the plasmid-mediated mcr-1 gene in isolates FRO and MAL was responsible for a four-fold increase in the MICs of colistin compared with the parental strains (2 mg/L to 8 mg/L for FRO and 8 mg/L to 32 mg/L for MAL).
This study indicates that an increase in resistance level to colistin may be achieved upon acquisition of the mcr-1 gene in strains harbouring chromosomally encoded mutations. The twostep process leading to a higher level of resistance to colistin mirrors what is known for quinolone resistance, with a plasmid determinant conferring low-level resistance that may facilitate further selection of chromosomally encoding mechanisms eventually leading to high-level resistance [7] . These results further highlight that acquisition of the mcr-1 gene may have a very significant clinical impact, contributing to a higher level of colistin resistance. Published in "International Journal of Antimicrobial Agents 50(3): 503-504, 2017" which should be cited to refer to this work.
